Background Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has
shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two …

Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options. …

Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms
that present many clinical challenges. They secrete peptides and neuroamines that cause …

Multiple endocrine neoplasia type 1 (MEN-1) is a predisposition to hyperplasia of the
parathyroid glands, and to hyperplasia or tumours of the anterior pituitary and the endocrine …

Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR),
has shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. …

M. Pavel a D. O’Toole b F. Costa c J. Capdevila d D. Gross e R. Kianmanesh f E. Krenning g
U. Knigge h R. Salazar i U.-F. Pape a K. Öberg j all other Vienna Consensus Conference …

Therapeutic approaches for management of metastatic disease include surgical, medical,
radiological and nuclear medicine strategies. More recently, novel molecular targeted drugs …

This consensus report gives a detailed description of the use of somatostatin analogs in the
management of neuroendocrine tumors of the gastroenteropancreatic system. As …

Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …

Endocrine pancreatic tumours (EPTs) are uncommon tumours occurring in approximately 1
in 100 000 of the population, representing 1–2% of all pancreatic neoplasms. Some of the …